Universal Ibogaine (FRA:JC4) FCF Margin %: -15.70% (As of Apr. 2025)


What is Universal Ibogaine FCF Margin %?

Universal Ibogaine FRA:JC4 FCF Margin % is -15.70% as of Apr. 2025.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Universal Ibogaine's Free Cash Flow for the three months ended in Apr. 2025 was €-0.07 Mil. Universal Ibogaine's Revenue for the three months ended in Apr. 2025 was €0.45 Mil. Therefore, Universal Ibogaine's FCF Margin % for the quarter that ended in Apr. 2025 was -15.70%.

As of today, Universal Ibogaine's current FCF Yield % is 0.00%.

The historical rank and industry rank for Universal Ibogaine's FCF Margin % or its related term are showing as below:

FRA:JC4' s FCF Margin % Range Over the Past 10 Years
Min: -32.47   Med: 0   Max: 0
Current: -32.47

FRA:JC4's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -82.65 vs FRA:JC4: -32.47

Universal Ibogaine FCF Margin % Related Terms

Universal Ibogaine FCF Margin % Historical Data

* Premium members only.

The historical data trend for Universal Ibogaine's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine FCF Margin % Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23 Jul24
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 -413.51 -141.42 -39.37

Universal Ibogaine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -96.72 -18.62 -57.69 -54.40 -15.70

FRA:JC4 vs LABT, CALC, LNAI: FCF Margin % Comparison

For the Biotechnology subindustry, Universal Ibogaine's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universal Ibogaine FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's FCF Margin % falls into.


Universal Ibogaine FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Universal Ibogaine's FCF Margin for the fiscal year that ended in Jul. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Jul. 2024 )/Revenue (A: Jul. 2024 )
=-0.617/1.567
=-39.37 %

Universal Ibogaine's FCF Margin for the quarter that ended in Apr. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Apr. 2025 )/Revenue (Q: Apr. 2025 )
=-0.07/0.446
=-15.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -15.70% mean?
Universal Ibogaine (FRA:JC4) has a FCF Margin % of -15.70% as of Apr. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Universal Ibogaine and its competitors.
Is Universal Ibogaine's FCF Margin % too high?
Universal Ibogaine's current FCF Margin % is -15.70%.
How does Universal Ibogaine's FCF Margin % compare to LABT and CALC?
Universal Ibogaine's FCF Margin % of -15.70% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Universal Ibogaine and its competitors. Universal Ibogaine's current FCF Margin % is -15.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (FRA:JC4) has a current FCF Margin % of -15.70%. The current FCF Margin % is -15.70%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Universal Ibogaine (FRA:JC4), the current FCF Margin % is -15.70% as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Universal Ibogaine Business Description

Address C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.